- 1 Title
- 2 A deep intronic variant in *MME* causes autosomal recessive Charcot-Marie-Tooth neuropathy
- 3 through aberrant splicing.
- 4 Authors
- 5 Bianca R Grosz^{1,2}, Jevin M Parmar^{3,4}, Melina Ellis^{1,2}, Samantha Bryen^{5,6}, Cas Simons^{5,6},
- 6 Andre L.M. Reis^{5,7,8}, Igor Stevanovski^{5,7}, Ira W. Deveson^{5,7,8}, Garth Nicholson^{2,11}, Nigel
- 7 Laing³, Mathew Wallis^{9,10}, Gianina Ravenscroft³, Kishore R. Kumar^{2,11,12,13}, Steve Vucic^{2,14},
- 8 Marina L Kennerson^{1,2,11}
- 9 ORCID:
- 10 Bianca R Grosz: 0000-0002-6926-0551
- 11 Jevin Parmar: 0000-0003-1864-8094
- 12 Melina Ellis: 0000-0002-8542-048X
- 13 Samantha Bryen: 0000-0002-4140-8622
- 14 Cas Simons: 0000-0003-3147-8042
- 15 Andre L.M Reis: 0000-0002-7300-1157
- 16 Igor Stevanovski: 0000-0002-7713-1979
- 17 Ira W Deveson: 0000-0003-3861-0472
- 18 Mathew Wallis: 0000-0002-5441-1732
- 19 Garth A Nicholson: 0000-0001-9694-066X
- 20 Nigel Laing: 0000-0001-5111-3732

- 21 Gianina Ravenscroft: 0000-0003-3634-211X
- 22 Kishore R Kumar: 0000-0003-3482-6962
- 23 Marina L Kennerson: 0000-0003-3332-5074

24

25 Affiliations:

- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, NSW 2139,
 Australia
- 28 2. The University of Sydney, Camperdown, NSW, 2050, Australia
- Rare Disease Genetics and Functional Genomics Research Group, Harry Perkins
 Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia,
 6009, Australia
- Centre for Medical Research, Faculty of Health and Medical Sciences, The University
 of Western Australia, Perth, WA 6009, Australia
- Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW
 Sydney, Sydney, NSW, Australia
- Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne,
 VIC, Australia
- Genomics and Inherited Disease Program, Garvan Institute of Medical Research,
 Sydney, NSW, Australia.
 - 8. Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
- Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, TAS,
 Australia.
- 10. School of Medicine and Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
- 11. Molecular Medicine Laboratory and Neurology Department, Concord Repatriation
 General Hospital, Hospital Rd, Concord, NSW, 2139, Australia
- 12. Translational Neurogenomics Group, Genomic and Inherited Disease Program, The
 Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010,
 Australia
 - 13. St Vincent's Healthcare Campus, Faculty of Medicine, UNSW Sydney, Level 5, De Lacy Building, St Vincent's Hospital, Darlinghurst, NSW, 2010, Australia.
- 14. Brain and Nerve Research Centre, The University of Sydney, Sydney, NSW 2139,
 Australia

54

50

51

40

- 57 Abstract
- **Background:** Loss-of-function variants in *MME* (membrane metalloendopeptidase) are a
- 59 known cause of recessive Charcot-Marie-Tooth Neuropathy (CMT). A deep intronic variant,
- 60 MME c.1188+428A>G (NM_000902.5), was identified through whole genome sequencing
- 61 (WGS) of two Australian families with recessive inheritance of axonal CMT using the seqr
- 62 platform. MME c.1188+428A>G was detected in a homozygous state in Family 1, and in a
- 63 compound heterozygous state with a known pathogenic MME variant (c.467del;
- p.Pro156Leufs*14) in Family 2.
- 65 **Aims:** We aimed to determine the pathogenicity of the MME c.1188+428A>G variant
- through segregation and splicing analysis.
- 67 **Methods:** The splicing impact of the deep intronic *MME* variant c.1188+428A>G was
- assessed using an *in vitro* exon-trapping assay.
- 69 **Results:** The exon-trapping assay demonstrated that the MME c.1188+428A>G variant
- 70 created a novel splice donor site resulting in the inclusion of an 83 bp pseudoexon between
- 71 MME exons 12 and 13. The incorporation of the pseudoexon into MME transcript is predicted
- 72 to lead to a coding frameshift and premature termination codon (PTC) in MME exon 14
- 73 (p.Ala397ProfsTer47). This PTC is likely to result in nonsense mediated decay (NMD) of
- 74 *MME* transcript leading to a pathogenic loss-of-function.
- 75 **Interpretation:** To our knowledge, this is the first report of a pathogenic deep intronic *MME*
- 76 variant causing CMT. This is of significance as deep intronic variants are missed using whole
- exome sequencing screening methods. Individuals with CMT should be reassessed for deep
- 78 intronic variants, with splicing impacts being considered in relation to the potential
- 79 pathogenicity of variants.
- 80 Key Words (up to 5): Charcot-Marie-Tooth disease, splicing, MME, recessive, deep intronic

Introduction

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

Charcot-Marie-Tooth neuropathy (CMT) is the most common inherited peripheral neuropathy, affecting 1/2500 individuals¹. CMT is characterized by progressive lengthdependent loss of peripheral motor and sensory nerves, resulting in distal muscle weakness and sensory symptoms². Patients are broadly divided into subtypes based on whether nerve conduction studies (NCS) indicating demyelinating (CMT1) or axonal (CMT2) forms of the disease. Recessive loss-of-function variants in the membrane metalloendopeptidase (MME) gene have been previously reported to cause axonal Charcot-Marie-Tooth neuropathy type 2T (CMT2T; OMIM: #617017)³⁻¹¹. MME encodes for neprilysin, a widely expressed membranebound metallopeptidase that has a key role in neuropeptide processing ¹². A significant portion of patients with axonal CMT remain genetically undiagnosed^{13–17}, indicating that further disease-causing genes and pathogenic variants in known genes are yet to be identified. Splicing variants are increasingly being recognized as a cause of Mendelian disease 18,19. The precise removal of introns (non-coding regions) and inclusion of exons (coding regions) in the final mature mRNA relies on the spliceosome and auxiliary splicing factors recognizing specific sequence motifs, such as the 5' donor splice site and 3' acceptor splice site. Splicealtering variants can weaken or abolish recognition of the correct splice sites, or alternatively strengthen or create cryptic splice sites that mimic consensus splicing sequences²⁰. These variants typically lead to one or more mis-splicing events that result in the skipping of partial or complete exons, and/or the retention of partial or complete introns ^{21–42}. Pathogenic splicing variants have been found in several CMT genes including $MPZ^{21,30,39,40}$, $MFN2^{22,30,31}$, $LRSAM1^{23}$, $IGHMBP2^{24}$, $INF2^{25}$, $MCM3AP^{26}$, $SH3TC2^{30,32,38}$, $GDAP1^{27,42}$, SBF1²⁸, NDRG1³⁷, and FGD4²⁹. Variants affecting canonical splice donor and acceptor sites have also been described in MME^{4,41}.

Exon-trapping, also known as a mini-gene assay, is an *in vitro* technique used to identify exons in a genomic region of interest⁴³. This is of particular use when relevant patient tissue is unavailable or when relevant transcripts may be unstable or degraded by nonsense mediated decay (NMD) 44. The genomic region of interest is cloned into an exon-trapping vector between two known exons. This exon-trapping vector is transfected into a cell line where it is transcribed and undergoes a series of post-transcriptional processes that include pre-mRNA splicing to create mature mRNA. This mRNA consists of the 'trapped' exons of the genomic region of interest flanked by the known exons, which can then be Sanger sequenced to characterize the 'trapped' exons, Comparison of 'trapped' exons between wild type and variant genomic sequences can also indicate if a candidate variant affects splicing 45-⁵¹. The well-validated exon-trapping vector pSpliceExpress ⁵² consists of known exons of the rat insulin gene, Ins2, and has been used previously to determine the splicing impacts of multiple pathogenic variants in Mendelian disease 45-51. Here we report a deep intronic variant in MME [chr3:155142758A>G (hg38); MME c.1188+428A>G], found in a recessive state in two Australian families. Exon-trapping revealed that this variant creates a novel splice donor site in MME intron 12 (NM_000902.5) which, along with a preceding existing cryptic splice acceptor site, results in the incorporation of an 83 bp pseudoexon in the MME transcript [chr3:155,142,675-155,142,757 (hg38); r.1188_1189ins[1188+345_1188+427]]. The coding frameshift caused by this pseudoexon leads to a PTC in exon 14 and likely NMD of the MME transcript

(p.Ala397ProfsTer47), resulting in a loss of *MME* function.

126

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

Materials and Methods:

127

Subjects 128 129 Members of Family 1 were recruited and informed consent was obtained for this study using 130 protocols approved by the Sydney Local Health District Human Ethics Research Committee 131 (2019/ETH07839). Recruitment and informed consent for the proband of Family 2 was 132 approved by the Human Research Ethics Committee of the Royal Melbourne Hospital 133 (HREC/16/MH/251). 134 Variant Detection 135 Genomic DNA for Family 1 was extracted from peripheral blood using the PureGene Kit 136 (Qiagen) following the manufacturer's instructions. WGS for two individuals in Family 1 137 (V:1 and V:3) was outsourced to the Garvan Sequencing Platform. Paired-end sequencing 138 reads of 150 base pairs were generated using the Illumina NovaSeq 6000 sequencing 139 machine, with 30-fold average read depth. 140 In Family 2, genomic DNA for the proband was extracted at the Department of Diagnostic Genomics (PathWest, Perth, Australia) using the QIAsymphonySP machine and 141 142 QIAsymphone® DSP DNA Midi Kit. The proband underwent WGS at the Australian 143 Genomics Research Facility (AGRF), Melbourne, following GATK4 best-practices. Paired-144 end sequencing reads of 150 base pairs were generated using the Illumina NovaSeq 6000 145 sequencing machine, with 30-fold average read depth. Parental DNA was not available for 146 sequencing. 147 WGS data processing was performed at the Centre for Population Genomics (CPG) following 148 the DRAGEN GATK best practices pipeline. Reads were aligned to the hg38 reference 149 genome using Dragmap (v1.3.0). Cohort-wide joint calling of single nucleotide variants 150 (SNVs) and small insertion/deletion (indel) variants was performed using GATK

HaplotypeCaller (v4.2.6.1) with "--dragen-mode" enabled. Sample sex and relatedness 151 quality checks were performed using Somalier (v0.2.15)⁵³. Variants were annotated using 152 VEP 105, and loaded into the web-based variant filtration platform, seqr⁵⁴. A WGS search 153 was conducted using the seqr⁴⁵ platform for low minor allele frequency (<0.01) variants in 154 155 1 2 CMT-related genes, for both Family and [gene list-Hereditary Neuropathy CMT IsolatedAndComplex (Version 2.14)⁵⁵]. Additionally, variants were 156 **CPG** Automated 157 analyzed by the Interpretation Pipeline (AIP, 158 https://github.com/populationgenomics/automated-interpretation-pipeline). In silico splicing analysis was conducted using SpliceAI⁵⁶. 159

160 Segregation Analysis

- The MME c.1188+428A>G variant in Family 1 and Family 2 was amplified using primers
- that spanned MME intron 12 (5'-CTCAGCCGAACCTACAAGGA-3'; 5'-
- 163 GCAAATGCTGCTTCCACAT-3') to produce a 1264 bp amplicon [chr3:155,142,289-
- 164 155,143,552 (hg38)]. An internal sequencing primer was used (5'-
- 165 CTGTGTTAAAAGTAATTTCGGGG-3') and the amplicon was Sanger sequenced. The
- 166 MME c.467del variant in Family 2 was amplified (5'-GCAGAGCCGTATGCATCACT-3';
- 167 5'-TTCAGCTGTCCAAGAAGCACC-3'). A 717bp amplicon was produced
- 168 [chr3:155,116,171-155,116,887 (hg38)], which was subsequently Sanger sequenced.

169

170

Sanger Sequencing

- For Family 1, PCR amplicons were sent to Garvan Molecular Genetics, Garvan Institute
- 172 (Sydney, Australia) for Sanger sequencing using BigDye Terminator cycle sequencing
- protocols. For Family 2, proband PCR amplicons were Sanger sequenced at AGRF, Perth
- using BigDye Terminator sequencing protocols. Sequences were visualized and analyzed
- using Snapgene Software version 7.1 (www.snapgene.com).

176

177

Oxford Nanopore Technologies (ONT) Long Read Sequencing

178 High molecular weight (HMW) DNA samples of the Proband in Family 2 were transferred to 179 the Garvan Sequencing Platform for targeted long-read sequencing analysis on ONT 180 instruments. Prior to ONT library preparations, DNA was sheared to ~20-25 kb fragment size using a MegaRuptor 3 instrument and visualized post-shearing on an Agilent FemtoPulse. 181 182 Sequencing libraries were prepared from ~3-5 µg of HMW DNA, using native library prep 183 kit SQK-LSK114, according to manufacturer's instructions. Each library was loaded onto a 184 R10.4.1 flow cell and sequenced on a PromethION device with live target selection/rejection executed by the ReadFish software package⁵⁷. Detailed descriptions of software and hardware 185 configurations used for ReadFish are provided in a previous publication⁵⁸. Samples were run 186 187 for a maximum duration of 72 h, with nuclease flushes and library reloading performed at 188 approximately 24- and 48-h timepoints for targeted sequencing runs, to maximize sequencing yield. Raw ONT sequencing data was converted to BLOW5 format⁵⁹ using slow5tools 189 (v.0.3.0)⁶⁰ then base-called using Guppy (v6). Resulting FASTQ files were aligned to the 190 hg38 reference genome using minimap2 (v2.14-r883)⁶¹. Variants were called using clair3⁶², 191 phased using Whatshap⁶³ and visualized using the Integrative Genomics Viewer (IGV, 192 v2.17.3)⁶⁴. 193

Cell Culture

194

195

196

197

198

The human HeLa cervical epithelial cell line (ATCC) was maintained in Dulbecco's Modified Eagle's Medium (DMEM)(Gibco) containing 10% (v/v) fetal bovine serum (FBS) (Gibco), +100 U/mL penicillin (Gibco), and 100 μg/mL streptomycin (Gibco) at 37°C in humidified air and 5% CO2.

Cloning Procedures

199

211

212

213

214

215

216

217

218

219

200 The region surrounding MME c.1188+428A>G [chr3:155,141,790-155,143,755 (hg38)] was 201 amplified from the genomic DNA of a heterozygous carrier of the c.1188+428A>G variant, 202 using attB adapter primers (5'-AAAAAGCAGGCTTCGCTCTTAAATGGTTGGCTT-3'; 5'-203 AGAAAGCTGGGTAACTAGACTCTTGGGGAAGGC -3'). The MME amplicon was then 204 cloned into the exon-trapping pSpliceExpress vector between flanking Ins2 exons using a 205 two-step Gateway cloning BP reaction (ThermoFisher). pSpliceExpress was a gift from Stefan Stamm (Addgene plasmid #32485)⁵². The pSpliceExpress-MME clones were then 206 207 Sanger sequenced to verify the correct insertion of MME and to determine the 208 c.1188+428A>G genotype of each clone (as the genomic DNA template was heterozygous 209 for the variant).

210 In vitro exon-trapping

HeLa cells were grown to approximately 70% confluence in a 6-well plate. HeLa cells were separately transfected with either 2 μg of pSpliceExpress-*MME*_{wT} or 2 μg of pSpliceExpress-*MME*_{wT} or 2 μg of pSpliceExpress-*MME*_{c.1188+428A>G} using Lipofectamine 3000 (ThermoFisher). RNA extraction was performed 48 h following transfection using the RNEasy Mini Kit (Qiagen), and reverse-transcribed template was prepared using the iScript cDNA Synthesis Kit (Bio-Rad). PCR amplification of cDNA was conducted using primers designed to anneal to the flanking *Ins2* exons (5'-CAGCACCTTTGTGGTTCTCA-3'; 5'-CAGTGCCAAGGTCTGAAGGT-3'). The RT-PCR amplicons were size fractionated using a 1.5% w/v agarose gel. The largest amplicon for each vector was gel-purified using Isolate II PCR and Gel Kit (Bioline) for Sanger Sequencing.

220 In silico splicing analysis of reported MME variants

All reported *MME* variants in gnomAD v.4.0.0 were detected by searching the gnomAD browser for the genomic region corresponding with the *MME* gene; '3-155024124-155183704'(hg38). The *MME* variants reported in gnomAD were then exported using the

'Export Variants to CSV' function. The consequences of the variants were described by gnomAD using the Variant Effect Predictor (VEP) annotation based on the most deleterious predicted functional effect of each variant 65 . These variants were then filtered for a minor allele frequency (MAF) <0.01 and a maximum SpliceAI Δ score >0.8 (high precision splicing change prediction 66) as annotated by gnomAD.

Results:

Clinical Phenotypes

Family 1 consists of four affected siblings from a consanguineous family of European (non-Finnish) background (Figure 1a). The phenotype was consistent with a generalized sensorimotor axonal neuropathy and sensory ataxia without cerebellar signs (Table 1), and was confirmed with NCS for individuals V:1 and V:6 (Table 2). Affected individuals had previously undergone diagnostic and research whole exome sequencing with negative results. Family 2 consists of one affected female born to a healthy, non-consanguineous couple (Figure 1b). Neurological examination revealed mild distal upper limb weakness and moderate distal lower limb weakness (Table 1). NCS showed evidence of an axonal sensorimotor neuropathy (Table 2). Bilateral MRI of the thighs and calves showed muscle atrophy (Supplementary Figure 1).

Genetic Analysis

244

245 WGS screening using the seqr platform in Family 1 revealed a single homozygous variant in 246 two affected individuals (V:1 and V:3), MME c.1188+428A>G (NM_000902.5). This variant was reported in dbSNP build 155⁶⁷ (rs61758195), with a low MAF in gnomAD v4.0.0⁶⁸ 247 (10/152120), All of Us $(35/490,748)^{69}$, and TOPMED⁷⁰ (15/264290). No homozygous 248 249 individuals were reported in gnomAD, All of Us, or TOPMED. SpliceAI predicted that MME 250 c.1188+428A>G could create a strong novel splice donor site (Score 0.97; where a SpliceAI 251 score above 0.8 is considered a 'high precision' predicted splice variant⁵⁶). This in turn 252 strengthened the SpliceAI prediction for a cryptic splice acceptor site 83 bp upstream of the 253 novel splice donor site (Score 0.99). 254 Segregation analysis in Family 1 confirmed the biallelic inheritance of the MME 255 c.1188+428A>G variant segregated with the CMT phenotype (Figure 1a). 256 sequencing of DNA from available individuals showed that all affected individuals were 257 homozygous for the MME c.1188+428A>G variant and unaffected individuals were carriers 258 (Supplementary Figure 2). 259 WGS screening using the seqr platform and AIP was conducted in the proband of Family 2 260 (II:1). The MME c.1188+428A>G variant was detected in a compound heterozygous state 261 with a second MME variant (MME c.467del; p.Pro156Leufs*14), which has previously been reported as pathogenic⁴¹ (Figure 1b). Sanger sequencing validated the presence of each MME 262 263 variant in the index individual (Supplementary Figure 3). As parental DNA was unavailable, 264 ONT long-read sequencing was conducted to phase the heterozygous MME variants in the 265 proband (Figure 1c-d). ONT long-read sequencing confirmed that MME c.1188+428A>G 266 (boxed red in Figure 1c) and c.467del (boxed red in Figure 1d) were present on alternative 267 haplotypes (hap-1: red, hap-2: blue) and therefore were in *trans* in the proband.

In vitro exon-trapping of *MME*-pSpliceExpress vectors

268

269

274

275

276

277

278

279

281

284

285

286

287

289

290

291

292

Two separate exon-trapping pSpliceExpress vectors were generated to assess the in vitro 270 splicing impact of the MME c.1188+428A>G variant: pSpliceExpress-MME_{WT} (wild-type) 271 and pSpliceExpress-MME_{c.1188+428A>G} (variant). A schematic of the constructs and relevant 272 SpliceAI scores are shown in Figure 2a. RT-PCR products produced following transfection of 273 these vectors were analyzed using gel electrophoresis (Figure 2b), which revealed a visible size difference between the wild-type (381 bp) and MME c.1188+428A>G amplicons (464 bp). The gel-purified amplicons were Sanger sequenced and the sequencing was aligned to the WT MME mRNA sequence. The sequenced products showed that the pSpliceExpress-MME_{WT} produced a transcript that was correctly spliced between MME exon 12 and 13 (Figure 2c). In contrast, exon-trapping of the pSpliceExpress-MME_{c.1188+428A>G} vector showed that an 83 bp pseudoexon had been spliced between MME exon 12 and 13 (Figure 2d). A BLAT search⁷¹ using the sequence of the trapped pseudoexon revealed alignment to the 280 intronic region directly upstream of the MME c.1188+428A>G variant [chr3:155,142,675-282 155,142,757 (hg38)]. This suggests that the MME c.1188+428A>G variant creates a novel 283 splice donor site leading to the aberrant inclusion of 83 bp of intronic MME sequence in the final spliced transcript, as predicted by SpliceAI. Prediction of the novel MME coding sequence caused by the introduction of the pseudoexon showed that a PTC was generated in exon 14 (p.Ala397ProfsTer47) at genomic position chr3:155,144,368 (hg38)(Supplementary Figure 4). This PTC likely leads to NMD of the *MME* transcript.

288 *In silico* splicing analysis of *MME* variants

All reported MME variants in gnomAD v.4.0.0 were assessed using the integrated SpliceAI scores to determine if splicing variants in MME were a likely underrecognized cause of disease. There were 37,264 total variants reported in MME in gnomAD, of which 35,673 variants had a MAF <0.01. Of these, 88 variants had a maximum SpliceAI Δscore above 0.8 (Supplementary Table 1). There were no homozygotes reported for any of the 88 *MME* putative splicing variants. The majority of these predicted splicing variants were predicted to directly change either the canonical splice donor sites (26/88) or canonical splice acceptor sites (30/88) of *MME*, including an inframe deletion (c.1317_1317+2del) and a frameshift variant (c.957+1del). An additional nine variants were predicted to affect a splicing region, including one which is also annotated as a synonymous variant (c.1188G>A; p.Lys396Lys). Nine missense variants (p.Asp209Gly, p.Ile217Ser, p.Glu282Val, p.Arg365Ile, p.Ser436Gly, p.Asp533Gly, p.Ile553Val, p.Val554Phe, p.Gln692Arg) and a synonymous variant (p.Gly417Gly) were also predicted to alter splicing. Twelve variants were annotated as 'intron variants', of which two could be considered 'deep intronic' variants (c.1188+428A>G, described in this manuscript, and c.197-9871A>G). Interestingly, further analysis using SpliceAI demonstrated that *MME* c.197-9871A>G was predicted to create a splice donor site (Score 0.81) and strengthen an upstream cryptic splice acceptor site (Score 0.81) in a similar manner to c.1188+428A>G, thereby possibly creating an in-frame 96 bp pseudoexon.

Discussion

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

Here we report a deep intronic variant, MME c.1188+428A>G causing recessive CMT2T in two unrelated Australian families. This variant results in a pseudoexon that likely leads to NMD of the MME transcript, resulting in a loss-of-function. This is in keeping with previously reported MME variants which have broadly been characterised as 'loss-offunction' variants. To our knowledge, this is the first report of a pathogenic deep intronic variant in MME. Given that a significant portion of patients with axonal CMT remain genetically undiagnosed¹³⁻¹⁷, it's possible that deep intronic variants in MME explain a portion of this diagnostic gap. Individuals from Family 1 previously underwent both diagnostic WES and research WES, and the proband in Family 2 previously underwent targeted gene panel testing (PathWest neuro v3). These testing methods did not capture deep intronic regions and returned negative results. However, deep intronic regions have previously been shown to have a higher prevalence of variants than coding regions and canonical splice sites⁷². Our findings suggest that intronic SNPs should be analyzed to determine if they impact splicing before they are dismissed as benign. Detection and functional validation of deep intronic variants has previously been shown to increase diagnostic rates in other Mendelian diseases including Xlinked Alport syndrome⁷³, inherited retinal disorders^{74,75}, and dystrophinopathy^{76,77}. Pathogenic deep intronic variants, such as described here, are likely to be underreported amongst CMT-causing genes due to a lack of detection by WES and targeted gene panels, and a lack of functional investigation upon detection. The MME c.1188+428A>G variant was reported in multiple different genetic ancestry groups in gnomAD v.4.0.0⁶⁸, including in the European (Non-Finnish) (8/68008), African/African American (1/41432), and 'remaining' (1/2092) ancestry groups. This was also reflected in the 'All of Us' Research Program⁶⁹, which reported the MME c.1188+428A>G variant in the African (2/107,888) and European populations (33/256,804). Whilst it is possible that MME c.1188+428A>G represents a recurrent de novo variant, it is also likely that this variant has persisted at low levels in the global population. As this variant is missed by WES and may not be prioritised by variant-filtering approaches focusing on coding variants, this variant may therefore represent an underappreciated cause of recessive CMT. This is further supported by its detection in two Australian CMT families who are not known to be related. Whilst the predicted splicing variants reported in MME are individually rare, we have described eighty-eight variants in gnomAD that are predicted by SpliceAI to alter splicing. Nine of these variants were annotated as missense variants, and one was a synonymous change. This is of note as these 'missense' variants are often assumed to result in a single amino acid change, and synonymous variants are often considered functionally neutral, with their effect on splicing typically not assessed⁷⁸. Our results suggest that the discovery of any of these eighty-eight variants in a homozygous or compound heterozygous state in an individual with CMT should prompt further functional investigation of their effect on splicing of the *MME* transcript. Prior to functional validation, MME c.1188+428A>G was considered a variant of uncertain significance (VUS) according to American College of Medical Genetics and Genomics (ACMG) criteria⁷⁹ (BP4, PM2, PM3, PP1), However, the functional evidence generated by the splicing assay now allows for the addition of PVS1 (null variant in a gene where loss-offunction is a known mechanism of disease) and PS3 (well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product) criteria. This

allows reclassification of the variant as 'pathogenic'. Therefore, this work demonstrates the

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

importance of functional validation to confirm the effect of candidate variants on splicing to increase diagnostic rates for those with inherited disease.

Previously described homozygous *MME* patients typically have a phenotype consistent with late-onset axonal neuropathy. In contrast, three of the four affected siblings in Family 1 described childhood onset and the proband of Family 2 described symptom onset in early adulthood. It has also previously been reported that heterozygous *MME* variants can cause spinocerebellar ataxia type 43 (SCA43)⁸⁰ as well as autosomal dominant CMT³. However, the individuals in Family 1 who were *MME* c.1188+428A>G heterozygotes were all clinically assessed as neurologically normal, including an individual who is in their seventh decade. Homozygous affected individuals in Family 1 were noted to have a sensory ataxia rather than cerebellar ataxia, although MRI brain studies were not conducted. Therefore, our findings here do not support a role for *MME* c.1188+428A>G to cause SCA43 or autosomal dominant CMT, and further expand the phenotype of recessive CMT2T.

Understanding the specific effects of splice-affecting variants is crucial for developing potential therapeutic strategies. Antisense oligonucleotides (ASOs) that modulate splicing are an active area of research, including individualized approaches to treat rare genetic diseases^{81–83}. Several antisense nucleotides that modify splicing have been approved by the United States Food and Drug Administration and have resulted in marked improvements in clinical outcomes in those with genetic diseases^{84–94}. An FDA-approved "n-of-1" ASO, milasen, successfully blocked pathogenic pseudoexon inclusion in *MFSD8* in a patient with neuronal ceroid lipofuscinosis type 7⁹⁴. ASOs which block pathogenic pseudoexons, such as that created by *MME* c.1188+428A>G, have also been described in *in vivo* preclinical models^{93,95–99}. As such, individuals with the *MME* c.1188+428A>G variant may represent a

form of CMT that is treatable through personalized ASO therapy and warrants further investigation.

Acknowledgements

This work was funded by the Medical Research Future Fund (MRFF) Genomics Health Futures Mission (APP2007681). JMP is supported by the Australian Government Research Training Program. IWD was supported by MRF2025138 & MRF2023126. Genomic analysis was supported by the Centre for Population Genomics (Garvan Institute of Medical Research and Murdoch Children's Research Institute) and was funded in part by a National Health and Medical Research Council investigator grant (2009982) and the Medical Research Future Fund (MRFF) Genomics Health Futures Mission (2008820).

Figure Legends:

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

Figure 1: The MME c.1188+428A>G (NM_000902.5) variant segregates with recessive **CMT in two families.** A) Family 1 pedigree showing the associated genotypes for the *MME* c.1188+428A>G (NM_000902.5) variant. Affected individuals in the fifth generation are homozygous (G/G). Unaffected individuals in the fifth (V) and sixth (VI) generation are heterozygous (A/G). Squares represent males and circles represent females, solid symbol denotes affected individual. The double line in the fourth (IV) generation indicates a consanguineous relationship. The MME c.1188+428 genotype is denoted beneath individuals who underwent Sanger sequencing, with the pathogenic 'G' allele in red text. B) A pedigree showing the associated genotypes for MME c.1188+428A>G and MME c.467del in the index individual in Family 2. C-D) Haplotype phasing showed that the c.1188+428A>G (C) and c.467del (D) variants were present on alternative haplotypes (light red and light blue), thus inherited in trans in the proband of Family 2. Phased targeted ONT long-read sequencing reads were visualized using the Integrative Genomics Viewer (IGV; v2.17.3). Figure 2. An exon-trapping assay was used to analyze splicing changes caused by the MME c.1188+428A>G variant. A) Schematic of the pSpliceExpress-MME_{WT} (wild-type) and pSpliceExpress-MME_{c.1188+428A>G} (variant) constructs. Both constructs consisted of an RSV LTR promoter region (blue) controlling transcription of a minigene of MME exons 12 and 13 (grey) flanked by Ins2 exon 2 and Ins2 exon 3 (black). The constructs differed in the presence of either an A (wild type: green text) or a G allele (mutant: red text) at MME c.1188+428A>G. i) The wild type sequence was not predicted to contain any strong splice sites when assessed using SpliceAI, with a score of 0.11 for the acceptor site (purple text) and 0.00 for the donor site (green text). ii) SpliceAI predicted that the MME c.1188+428A>G variant (red arrow) would create a strong splice donor site [Score: 0.97 (Δ 0.97); red text], which then strengthened the prediction of a splice acceptor site 83 bp upstream [Score 0.99] (Δ0.97); purple text]. The predicted 83 bp pseudoexon sequence is capitalized and boxed in red. B) The amplicon produced by the pSpliceExpress-*MME*_{c.1188+428A>G} vector (464 bp) showed a visible increase in product size when compared to the amplicon produced by pSpliceExpress-*MME*_{WT} (381 bp). The 158 bp RT-PCR product produced by both vectors indicated splicing and ligation of the flanking *Ins2* exon 2 and exon 3. Lanes: L: HyperLadder 100 bp (Bioline); WT: wild-type; NRTC: negative cDNA conversion control (no reverse transcriptase). NTC: negative PCR reaction control (no cDNA template). C) Sanger sequencing of the pSpliceExpress-*MME*_{WT} RT-PCR product confirmed correct splicing between *MME* exon 12 and 13. D) Sanger sequencing of the pSpliceExpress-*MME*_{c.1188+428A>G} RT-PCR product revealed the presence of a novel 83 bp pseudoexon (red) between *MME* exon 12 and 13. Abbreviations: RSV LTR: Rous Sarcoma Virus Long Terminal Repeat promoter; *Ins2*: rat preproinsulin 2 gene.

430 431	Refe	erences
432 433	1.	Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. <i>Clin Genet</i> . 1974;6:98-118.
434 435	2.	Szigeti K, Lupski JR. Charcot–Marie–Tooth disease. <i>European Journal of Human Genetics</i> . 2009;17(6):703-710. doi:10.1038/ejhg.2009.31
436 437 438	3.	Senderek J, Lassuthova P, Kabzińska D, et al. The genetic landscape of axonal neuropathies in the middle-aged and elderly. <i>Neurology</i> . 2020;95(24). doi:10.1212/WNL.000000000011132
439 440	4.	Higuchi Y. Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2. <i>Ann Neurol</i> . 2016;79:659-672.
441 442 443	5.	Record CJ, Pipis M, Skorupinska M, et al. Whole genome sequencing increases the diagnostic rate in Charcot-Marie-Tooth disease. <i>Brain</i> . Published online March 14, 2024. doi:10.1093/brain/awae064
444 445 446 447	6.	Jamiri Z, Khosravi R, Heidari MM, Kiani E, Gharechahi J. A nonsense mutation in <scp> <i>MME</i> </scp> gene associates with autosomal recessive late □ onset <scp> Charcot−Marie−Tooth</scp> disease. <i>Mol Genet Genomic Med.</i> 2022;10(5). doi:10.1002/mgg3.1913
448 449 450	7.	Taghizadeh S, Vazehan R, Beheshtian M, et al. Molecular Diagnosis of Hereditary Neuropathies by Whole Exome Sequencing and Expanding the Phenotype Spectrum. <i>Arch Iran Med.</i> 2020;23(7):426-433. doi:10.34172/AIM.2020.39
451 452 453	8.	Ando M, Higuchi Y, Yuan J, et al. Comprehensive Genetic Analyses of Inherited Peripheral Neuropathies in Japan: Making Early Diagnosis Possible. <i>Biomedicines</i> . 2022;10(7):1546. doi:10.3390/biomedicines10071546
454 455 456	9.	Megarbane A, Bizzari S, Deepthi A, et al. A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort. <i>J Neuromuscul Dis</i> . 2022;9(1):193-210. doi:10.3233/JND-210652
457 458 459	10.	Høyer H, Hilmarsen HT, Sunder-Plassmann R, et al. A polymorphic AT-repeat causes frequent allele dropout for an <i>MME</i> mutational hotspot exon. <i>J Med Genet</i> . 2022;59(10):1024-1026. doi:10.1136/jmedgenet-2021-108281
460 461 462 463	11.	Dupuis M, Raymackers JM, Ackermans N, Boulanger S, Verellen-Dumoulin C. Hereditary axonal neuropathy related to MME gene mutation in a family with fetomaternal alloimmune glomerulonephritis. <i>Acta Neurol Belg.</i> 2020;120(1):149-154. doi:10.1007/s13760-020-01275-9
464	12.	Krämer HH, He L, Lu B, Birklein F, Sommer C. Increased pain and neurogenic

inflammation in mice deficient of neutral endopeptidase. Neurobiol Dis.

2009;35(2):177-183. doi:10.1016/j.nbd.2008.11.002

465

- 467 13. Gemelli C, Geroldi A, Massucco S, et al. Genetic Workup for Charcot-Marie-Tooth
- Neuropathy: A Retrospective Single-Site Experience Covering 15 Years. *Life (Basel)*.
- 469 2022;12(3). doi:10.3390/life12030402
- 470 14. Candayan A, Parman Y, Battaloğlu E. Clinical and Genetic Survey for Charcot-Marie-
- 471 Tooth Neuropathy Based on the Findings in Turkey, a Country with a High Rate of
- 472 Consanguineous Marriages. *Balkan Med J.* 2022;39(1):3.
- doi:10.4274/BALKANMEDJ.GALENOS.2021.2021-11-13
- 474 15. Rudnik-Schöneborn S, Tölle D, Senderek J, et al. Diagnostic algorithms in Charcot-
- 475 Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis
- of 1206 index patients. Clin Genet. 2016;89(1):34-43. doi:10.1111/cge.12594
- 477 16. Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients
- enrolled in the Inherited Neuropathies Consortium natural history study: a cross-
- 479 sectional analysis. 2015;86(8):873-878. doi:10.1136/jnnp-2014-308826
- 480 17. Ma Y, Duan X, Liu X, Fan D. Clinical and mutational spectrum of paediatric Charcot-
- Marie-Tooth disease in a large cohort of Chinese patients. *Front Genet*. 2023;14.
- 482 doi:10.3389/fgene.2023.1188361
- 483 18. Lord J, Baralle D. Splicing in the Diagnosis of Rare Disease: Advances and
- 484 Challenges. Front Genet. 2021;12:689892. doi:10.3389/fgene.2021.689892
- 485 19. Wang R, Helbig I, Edmondson AC, Lin L, Xing Y. Splicing defects in rare diseases:
- transcriptomics and machine learning strategies towards genetic diagnosis. *Brief*
- 487 *Bioinform*. 2023;24(5). doi:10.1093/bib/bbad284
- 488 20. Anna A, Monika G. Splicing Mutations in Human Genetic Disorders: Examples,
- 489 Detection, and Confirmation. Vol 59. Springer Verlag; 2018:253-268.
- 490 doi:10.1007/s13353-018-0444-7
- 491 21. Corrado L, Magri S, Bagarotti A, et al. A novel synonymous mutation in the MPZ
- gene causing an aberrant splicing pattern and Charcot-Marie-Tooth disease type 1b.
- 493 Neuromuscular Disorders. 2016;26(8):516-520. doi:10.1016/j.nmd.2016.05.011
- 494 22. Boaretto F, Vettori A, Casarin A, et al. Severe CMT type 2 with fatal encephalopathy
- associated with a novel MFN2 splicing mutation. *Neurology*. 2010;74(23).
- 496 doi:10.1212/WNL.0b013e3181e240f9
- 497 23. Engeholm M, Sekler J, Schöndorf DC, et al. A novel mutation in LRSAM1 causes
- 498 axonal Charcot-Marie-Tooth disease with dominant inheritance. *BMC Neurol*.
- 499 2014;14(1):118. doi:10.1186/1471-2377-14-118
- 500 24. Cassini TA, Duncan L, Rives LC, et al. Whole genome sequencing reveals novel
- 501 *IGHMBP2* variant leading to unique cryptic splice ☐ site and Charcot ☐ Marie ☐ Tooth
- phenotype with early onset symptoms. *Mol Genet Genomic Med*. 2019;7(6):e00676.
- 503 doi:10.1002/mgg3.676
- 504 25. Echaniz □ Laguna A, Latour P, Echaniz Laguna A, Latour P, Echaniz □ Laguna A,
- Latour P. A cryptic splicing mutation in the INF2 gene causing Charcot-Marie-Tooth

- disease with minimal glomerular dysfunction. *Journal of the Peripheral Nervous System.* 2019;24(1):120-124. doi:10.1111/jns.12308
- 508 26. Ylikallio E, Woldegebriel R, Tumiati M, et al. MCM3AP in recessive Charcot-Marie-509 Tooth neuropathy and mild intellectual disability. *Brain*. 2017;140(8):2093-2103. 510 doi:10.1093/brain/awx138
- Numakura C, Lin C, Ikegami T, Guldberg P, Hayasaka K. Molecular analysis in
 Japanese patients with Charcot-Marie-Tooth disease: DGGE analysis for PMP22,
- 513 MPZ, and Cx32/GJB1 mutations. *Hum Mutat*. 2002;20(5):392-398.
- doi:10.1002/humu.10134
- 515 28. Flusser H, Halperin D, Kadir R, Shorer Z, Shelef I, Birk OS. Novel SBF1 splice-site 516 null mutation broadens the clinical spectrum of Charcot-Marie-Tooth type 4B3 517 disease. *Clin Genet*. 2018;94(5):473-479. doi:10.1111/cge.13419
- Hayashi M, Abe A, Murakami T, et al. Molecular analysis of the genes causing recessive demyelinating Charcot-Marie-Tooth disease in Japan. *J Hum Genet*. 2013;58(5):273-278. doi:10.1038/jhg.2013.15
- 521 30. DiVincenzo C, Elzinga CD, Medeiros AC, et al. The allelic spectrum of Charcot-522 Marie-Tooth disease in over 17,000 individuals with neuropathy. *Mol Genet Genomic* 523 *Med.* 2014;2(6):522-529. doi:10.1002/mgg3.106
- Martikainen MH, Kytövuori L, Majamaa K. Novel mitofusin 2 splice-site mutation
 causes Charcot–Marie–Tooth disease type 2 with prominent sensory dysfunction.
 Neuromuscular Disorders. 2014;24(4):360-364. doi:10.1016/J.NMD.2014.01.007
- 527 32. Piscosquito G, Saveri P, Magri S, et al. Screening for SH3TC2 gene mutations in a 528 series of demyelinating recessive Charcot-Marie-Tooth disease (CMT4). *J Peripher* 529 *Nerv Syst.* 2016;21(3):142-149. doi:10.1111/jns.12175
- 530 33. Benedetti S, Previtali SC, Coviello S, et al. Analyzing histopathological features of rare Charcot-Marie-Tooth neuropathies to unravel their pathogenesis. *Arch Neurol*. 2010;67(12):1498-1505. doi:10.1001/archneurol.2010.303
- Li MY, Yin M, Yang L, et al. A novel splicing mutation in 5'UTR of GJB1 causes X-linked Charcot—Marie—tooth disease. *Mol Genet Genomic Med*. 2023;11(3):e2108.
 doi:10.1002/MGG3.2108
- 536 35. Boso F, Taioli F, Cabrini I, Cavallaro T, Fabrizi GM. Aberrant Splicing in GJB1 and the Relevance of 5' UTR in CMTX1 Pathogenesis. *Brain Sci.* 2020;11(1):24. doi:10.3390/brainsci11010024
- Tomaselli PJPPJ, Rossor AM, Horga A, et al. Mutations in noncoding regions in GJB1
 are a major cause of X-linked CMT. *Neurology*. 2017;88(15):1445-1453.
 doi:10.1212/WNL.0000000000003819
- 542 37. Pravinbabu P, Holla V V, Phulpagar P, et al. A splice altering variant in NDRG1 gene 543 causes Charcot-Marie-Tooth disease, type 4D. *Neurol Sci.* 2022;43(7):4463-4472. 544 doi:10.1007/s10072-022-05893-4

- 545 38. Shchagina O, Orlova M, Murtazina A, Filatova A, Skoblov M, Dadali E. Evaluation of
- Pathogenicity and Causativity of Variants in the MPZ and SH3TC2 Genes in a Family
- Case of Hereditary Peripheral Neuropathy. *Int J Mol Sci.* 2023;24(12).
- 548 doi:10.3390/ijms24129786
- 549 39. Taioli F, Cabrini I, Cavallaro T, Simonati A, Testi S, Fabrizi GM. Déjerine-Sottas
- syndrome with a silent nucleotide change of myelin protein zero gene. *Journal of the*
- 551 *Peripheral Nervous System.* 2011;16(1):59-64. doi:10.1111/j.1529-8027.2011.00319.x
- 552 40. Sabet A, Li J, Ghandour K, et al. Skin biopsies demonstrate MPZ splicing
- abnormalities in Charcot-Marie-Tooth neuropathy 1B. *Neurology*. 2006;67(7):1141-
- 554 1146. doi:10.1212/01.wnl.0000238499.37764.b1
- 555 41. Lupo V. Characterising the phenotype and mode of inheritance of patients with
- inherited peripheral neuropathies carrying MME mutations. *J Med Genet*.
- 557 2018;55:814-823.
- 558 42. Masingue M, Perrot J, Carlier RY, Piguet-Lacroix G, Latour P, Stojkovic T. WES
- homozygosity mapping in a recessive form of Charcot-Marie-Tooth neuropathy
- reveals intronic GDAP1 variant leading to a premature stop codon. *Neurogenetics*.
- 561 2018;19(2):67-76. doi:10.1007/s10048-018-0539-7
- 562 43. Duyk GM, Kim SW, Myers RM, Cox DR. Exon trapping: a genetic screen to identify
- 563 candidate transcribed sequences in cloned mammalian genomic DNA. *Proceedings of*
- *the National Academy of Sciences*. 1990;87(22):8995-8999.
- doi:10.1073/pnas.87.22.8995
- 566 44. Micale L, Morlino S, Schirizzi A, et al. Exon-Trapping Assay Improves Clinical
- Interpretation of COL11A1 and COL11A2 Intronic Variants in Stickler Syndrome
- Type 2 and Otospondylomegaepiphyseal Dysplasia. *Genes (Basel)*. 2020;11(12):1513.
- doi:10.3390/genes11121513
- 570 45. Grosz BR, Tisch S, Tchan MC, et al. A novel synonymous KMT2B variant in a patient
- with dystonia causes aberrant splicing. *Mol Genet Genomic Med*. 2022;10(5).
- 572 doi:10.1002/MGG3.1923
- 573 46. Mutai H, Wasano K, Momozawa Y, et al. Variants encoding a restricted carboxy-
- terminal domain of SLC12A2 cause hereditary hearing loss in humans. *PLoS Genet*.
- 575 2020;16(4). doi:10.1371/journal.pgen.1008643
- 576 47. Knapp KM, Sullivan R, Murray J, et al. Linked-read genome sequencing identifies
- 577 biallelic pathogenic variants in DONSON as a novel cause of Meier-Gorlin syndrome.
- 578 J Med Genet. 2020;57(3):195-202. doi:10.1136/jmedgenet-2019-106396
- 579 48. Starokadomskyy P, Gemelli T, Rios JJ, et al. DNA polymerase-α regulates the
- activation of type i interferons through cytosolic RNA:DNA synthesis. *Nat Immunol*.
- 581 2016;17(5):495-504. doi:10.1038/ni.3409
- 582 49. Varga L, Danis D, Skopkova M, et al. Novel EYA4 variant in Slovak family with late
- onset autosomal dominant hearing loss: A case report. *BMC Med Genet*. 2019;20(1).
- 584 doi:10.1186/s12881-019-0806-y

- 585 50. Legendre M, Rodriguez-Ballesteros M, Rossi M, et al. CHARGE syndrome: A
- recurrent hotspot of mutations in CHD7 IVS25 analyzed by bioinformatic tools and
- 587 minigene assays /631/208 /692/308 brief-communication. European Journal of Human
- 588 Genetics. 2018;26(2):287-292. doi:10.1038/s41431-017-0007-0
- 589 51. Abdulhay NJ, Fiorini C, Verboon JM, et al. Impaired human hematopoiesis due to a
- cryptic intronic GATA1 splicing mutation. *Journal of Experimental Medicine*.
- 591 2019;216(5):1050-1060. doi:10.1084/jem.20181625
- 592 52. Kishore S, Khanna A, Stamm S. Rapid generation of splicing reporters with
- pSpliceExpress. Gene. 2008;427(1-2):104-110. doi:10.1016/j.gene.2008.09.021
- 594 53. Pedersen BS, Bhetariya PJ, Brown J, et al. Somalier: rapid relatedness estimation for
- cancer and germline studies using efficient genome sketches. *Genome Med*.
- 596 2020;12(1):62. doi:10.1186/s13073-020-00761-2
- 597 54. Pais LS, Snow H, Weisburd B, et al. seqr: A web-based analysis and collaboration tool
- for rare disease genomics. *Hum Mutat*. 2022;43(6):698-707.
- 599 doi:10.1002/HUMU.24366
- 55. Stark Z, Foulger RE, Williams E, et al. Scaling national and international improvement
- in virtual gene panel curation via a collaborative approach to discordance resolution.
- 602 Am J Hum Genet. 2021;108(9):1551-1557. doi:10.1016/j.ajhg.2021.06.020
- 56. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting Splicing
- from Primary Sequence with Deep Learning. *Cell*. 2019;176(3):535-548.e24.
- doi:10.1016/j.cell.2018.12.015
- 606 57. Payne A, Holmes N, Clarke T, Munro R, Debebe BJ, Loose M. Readfish enables
- targeted nanopore sequencing of gigabase-sized genomes. *Nat Biotechnol*.
- 608 2021;39(4):442-450. doi:10.1038/s41587-020-00746-x
- 58. Stevanovski I, Chintalaphani SR, Gamaarachchi H, et al. Comprehensive genetic
- 610 diagnosis of tandem repeat expansion disorders with programmable targeted nanopore
- sequencing. *Sci Adv.* 2022;8(9). doi:10.1126/SCIADV.ABM5386
- 612 59. Gamaarachchi H, Samarakoon H, Jenner SP, et al. Fast nanopore sequencing data
- 613 analysis with SLOW5. *Nat Biotechnol*. 2022;40(7):1026-1029. doi:10.1038/s41587-
- 614 021-01147-4
- 615 60. Samarakoon H, Ferguson JM, Jenner SP, et al. Flexible and efficient handling of
- nanopore sequencing signal data with slow5tools. Genome Biol. 2023;24(1):69.
- doi:10.1186/s13059-023-02910-3
- 61. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics*.
- 619 2018;34(18):3094-3100. doi:10.1093/bioinformatics/bty191
- 620 62. Zheng Z, Li S, Su J, Leung AWS, Lam TW, Luo R. Symphonizing pileup and full-
- alignment for deep learning-based long-read variant calling. *Nat Comput Sci.*
- 622 2022;2(12):797-803. doi:10.1038/s43588-022-00387-x

- 623 63. Martin M, Patterson M, Garg S, et al. WhatsHap: fast and accurate read-based phasing.
 624 Published online 2016. doi:10.1101/085050
- 625 64. Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative Genomics Viewer. *Nat Biotechnol.* 2011;29(1):24. doi:10.1038/NBT.1754
- 627 65. Zeng Z, Bromberg Y. Predicting Functional Effects of Synonymous Variants: A
 628 Systematic Review and Perspectives. Front Genet. 2019;0:914.
- doi:10.3389/FGENE.2019.00914
- 630 66. Kishore Jaganathan A, Kyriazopoulou Panagiotopoulou S, McRae JF, et al. Predicting
- Splicing from Primary Sequence with Deep Learning In Brief A deep neural network
- precisely models mRNA splicing from a genomic sequence and accurately predicts
- noncoding cryptic splice mutations in patients with rare genetic diseases. Predicting
- Splicing from Primary Sequence with Deep Learning. *Cell*. 2018;176:535-548.
- 635 doi:10.1016/j.cell.2018.12.015
- 636 67. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic
- 637 variation. *Nucleic Acids Res.* 2001;29(1):308-311. Accessed March 5, 2019.
- http://www.ncbi.nlm.nih.gov/pubmed/11125122
- 639 68. Chen S, Francioli LC, Goodrich JK, et al. A genomic mutational constraint map using variation in 76,156 human genomes. *Nature*. 2024;625(7993):92-100.
- doi:10.1038/s41586-023-06045-0
- 642 69. All of Us Research Program Investigators, Denny JC, Rutter JL, et al. The "All of Us" Research Program. *N Engl J Med*. 2019;381(7):668-676. doi:10.1056/NEJMsr1809937
- 70. Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from
- the NHLBI TOPMed Program. *Nature*. 2021;590(7845):290-299. doi:10.1038/s41586-
- 646 021-03205-y
- 71. Kent WJ. <tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool. *Genome Res.* 2002;12(4):656-664. doi:10.1101/gr.229202
- 649 72. Castle JC. SNPs occur in regions with less genomic sequence conservation. *PLoS One*.
- 650 2011;6(6):e20660. doi:10.1371/journal.pone.0020660
- 651 73. Boisson M, Arrondel C, Cagnard N, et al. A wave of deep intronic mutations in X-
- linked Alport syndrome. *Kidney Int.* 2023;104(2):367-377.
- doi:10.1016/j.kint.2023.05.006
- 654 74. Qian X, Wang J, Wang M, et al. Identification of Deep-Intronic Splice Mutations in a
- Large Cohort of Patients With Inherited Retinal Diseases. *Front Genet*.
- 656 2021;12:647400. doi:10.3389/fgene.2021.647400
- 657 75. Di Scipio M, Tavares E, Deshmukh S, et al. Phenotype Driven Analysis of Whole
- 658 Genome Sequencing Identifies Deep Intronic Variants that Cause Retinal Dystrophies
- by Aberrant Exonization. *Invest Ophthalmol Vis Sci.* 2020;61(10):36.
- doi:10.1167/iovs.61.10.36

- 76. Xie Z, Sun C, Liu Y, et al. Practical approach to the genetic diagnosis of unsolved
- dystrophinopathies: a stepwise strategy in the genomic era. *J Med Genet*.
- 2021;58(11):743-751. doi:10.1136/jmedgenet-2020-107113
- 77. Zaum AK, Stüve B, Gehrig A, et al. Deep intronic variants introduce DMD
- pseudoexon in patient with muscular dystrophy. *Neuromuscul Disord*. 2017;27(7):631-
- 666 634. doi:10.1016/j.nmd.2017.04.003
- 667 78. Anna A, Monika G. Splicing mutations in human genetic disorders: examples,
- detection, and confirmation. J Appl Genet. 2018;59(3):253-268. doi:10.1007/s13353-
- 669 018-0444-7
- 670 79. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of
- sequence variants: A joint consensus recommendation of the American College of
- Medical Genetics and Genomics and the Association for Molecular Pathology.
- 673 Genetics in Medicine. 2015;17(5):405-424. doi:10.1038/gim.2015.30
- 674 80. Depondt C, Donatello S, Rai M, et al. MME mutation in dominant spinocerebellar
- ataxia with neuropathy (SCA43). Neurol Genet. 2016;2(5):e94.
- doi:10.1212/NXG.0000000000000094
- 81. Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching
- oligonucleotide therapy. *Nature*. 2023;619(7971):828-836. doi:10.1038/s41586-023-
- 679 06277-0
- 680 82. Chen S, Heendeniya SN, Le BT, et al. Splice-Modulating Antisense Oligonucleotides
- as Therapeutics for Inherited Metabolic Diseases. *BioDrugs*. 2024;38(2):177-203.
- doi:10.1007/s40259-024-00644-7
- 83. Santos JI, Gonçalves M, Matos L, et al. Splicing Modulation as a Promising
- Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses
- Example. *Life*. 2022;12(5):608. doi:10.3390/life12050608
- 686 84. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of
- Duchenne muscular dystrophy. *Ann Neurol*. 2013;74(5):637-647.
- 688 doi:10.1002/ana.23982
- 689 85. Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen
- in patients with Duchenne muscular dystrophy. *Neurology*. 2020;94(21):e2270-e2282.
- doi:10.1212/WNL.0000000000009233
- 692 86. Heo YA. Golodirsen: First Approval. *Drugs*. 2020;80(3):329-333.
- 693 doi:10.1007/s40265-020-01267-2
- 694 87. Clemens PR, Rao VK, Connolly AM, et al. Safety, Tolerability, and Efficacy of
- 695 Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53
- 696 Skipping: A Phase 2 Randomized Clinical Trial. *JAMA Neurol*. 2020;77(8):982-991.
- 697 doi:10.1001/jamaneurol.2020.1264
- 698 88. Shirley M. Casimersen: First Approval. *Drugs*. 2021;81(7):875-879.
- doi:10.1007/s40265-021-01512-2

- 700 89. Wurster CD, Winter B, Wollinsky K, et al. Intrathecal administration of nusinersen in
- adolescent and adult SMA type 2 and 3 patients. *J Neurol*. 2019;266(1):183-194.
- 702 doi:10.1007/s00415-018-9124-0
- 703 90. Osredkar D, Jílková M, Butenko T, et al. Children and young adults with spinal
- muscular atrophy treated with nusinersen. Eur J Paediatr Neurol. 2021;30:1-8.
- 705 doi:10.1016/j.ejpn.2020.11.004
- 706 91. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-
- 707 Onset Spinal Muscular Atrophy. *N Engl J Med*. 2018;378(7):625-635.
- 708 doi:10.1056/NEJMoa1710504
- 709 92. Bianchi L, Sframeli M, Vantaggiato L, et al. Nusinersen Modulates Proteomics
- Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients. *Int J Mol*
- 711 *Sci.* 2021;22(9). doi:10.3390/ijms22094329
- 712 93. Kim J, Woo S, de Gusmao CM, et al. A framework for individualized splice-switching
- 713 oligonucleotide therapy. *Nature*. 2023;619(7971):828-836. doi:10.1038/s41586-023-
- 714 06277-0
- 715 94. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide
- Therapy for a Rare Genetic Disease. *N Engl J Med*. 2019;381(17):1644-1652.
- 717 doi:10.1056/NEJMoa1813279
- 718 95. Yamada M, Maeta K, Suzuki H, et al. Successful skipping of abnormal pseudoexon by
- antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated
- 720 neurodegeneration. *Sci Rep.* 2024;14(1):6506. doi:10.1038/s41598-024-56704-z
- 721 96. Aguti S, Bolduc V, Ala P, et al. Exon-Skipping Oligonucleotides Restore Functional
- 722 Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD. *Mol Ther*
- 723 Nucleic Acids. 2020;21:205-216. doi:10.1016/J.OMTN.2020.05.029
- 724 97. Kim J, Hu C, Moufawad El Achkar C, et al. Patient-Customized Oligonucleotide
- 725 Therapy for a Rare Genetic Disease. *N Engl J Med*. 2019;381(17):1644-1652.
- 726 doi:10.1056/NEJMOA1813279
- 727 98. Dominov JA, Uyan Ö, McKenna Yasek D, et al. Correction of pseudoexon splicing
- caused by a novel intronic dysferlin mutation. Ann Clin Transl Neurol. 2019;6(4):642-
- 729 654. doi:10.1002/acn3.738

- 730 99. Martínez-Pizarro A, Leal F, Holm LL, et al. Antisense Oligonucleotide Rescue of
- 731 Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin
- 732 Synthase Gene. Nucleic Acid Ther. 2022;32(5):378-390. doi:10.1089/nat.2021.0066

Table 1. Phenotypic characterization of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations- AFO: Ankle foot orthoses; CMTNS: Charcot-Marie-Tooth Neuropathy Score; UL/LL: Upper Limb/Lower Limb

Family #	Family 1	Family 2			
Individual	V:1	V:3	V:4	V:6	II:1
Sex	M	F	M	M	F
Onset	Fourth decade	Childhood	Childhood	Childhood	Early-adult
Age at evaluation	60-65	65-70	65-70	65-70	50-55
(years)					
Presenting symptom	Gait unsteadiness	Difficulty running	Difficulty sitting on crossed	Difficulty running,	Bilateral leg weakness
			legs during childhood	multiple ankle sprains	and sensory disturbance
Atrophy UL/LL	Yes/yes	Yes/yes	Yes/yes	Yes/yes	No/Yes
					(left calf only)
Foot deformity	None	Pes cavus/hammer toes	-	Pes cavus	Pes cavus
Tone UL/LL	Normal/reduced	Normal/normal	Normal, increased		Normal/normal
Shoulder abduction	5	5	3	5	4
Elbow flexion	4	5	3	4	5
Elbow extension	4	5	3	4	5

Finger abduction	2	4	3	1	4
Hip flexion	4	3	3	3	4
Knee extension	4	3	3	4	4
Knee flexion	4	3	3	4	4
Ankle dorsiflexion	0	0	3	1	3
Ankle plantarflexion	0	0	3	0	4
Deep tendon	Absent/absent	Absent ankle	Hyperreflexia knee, absent	Absent/absent	Normal/ reduced ankle
reflexes UL/LL			ankle		reflexes
Plantars	Absent	-	Absent	Flexor	Flexor
Proprioception	Normal/reduced to	-	-	Normal/reduced to the	Normal/reduced to ankle
UL/LL	the MTP			ankle	
Vibration UL/LL	Normal/reduced to	Absent in toes	-	Reduced to	Reduced to mid-shin
	ankle			wrist/reduced to knees	
Pinprick UL/LL	Normal/reduced to	Normal/reduced to the	Reduced to elbows/reduced	Reduced to PIP	Reduced to mid-shin
	ankle	mid shin	to knees	joint/reduced to knees	Reduced dorsum hand
Temperature	Normal/reduced to	-	-	Reduced to	Reduced to mid-shin
sensation UL/LL	ankle			wrist/reduced to above	

				knee	
Other	Cough	GORD and cough	Corticospinal tract signs	Nil	Fatty infiltration on left
symptoms/signs					gastrocnemius
Gait	High steppage/ataxic	High steppage/ataxic	Steppage gait	High steppage/ataxic	High steppage
Romberg's sign	Positive	Positive		Positive	Mild sway
Mobility aids	AFO, walking stick	AFO, walker	AFO, walker, mobility	Wheelchair	AFO, elbow crutch
	and mobility scooter		scooter		
CMTNS (version 2)	31	-	28/36	36	15

Table 2. Nerve conduction study (NCS) findings of individuals with recessive CMT *MME* variants reported in this manuscript. Abbreviations: APB: abductor pollicis brevis; ADM: abductor digiti minimi; EDB: extensor hallucis brevis; FHB: flexor hallus brevis; CMAP: compound motor action potential; CV: conduction velocity; NR: no response; SNAP: sensory nerve action potential; R: right, L:left.

Family #	Family 1		Family 2	
Individual	V:1	V:6	II:1	
Age at NCS (years)	60-65	65-70	55-60	
Median nerve (digit II) [orthod	dromic(R)]		<u> </u>	
SNAP (uV)	NR	NR	6.6	
CV (m/s)	NR	NR	50	
Ulnar nerve (digit V) [orthodr	omic(R)]			
SNAP (uV)	NR	1	4.9	
CV (m/s)	NR	40.2	51	
Sural nerve [orthodromic(R)]				
SNAP (uV)	NR	NR	NR	
CV (m/s)	NR	NR	NR	
Sural nerve [orthodromic(L)]				

SNAP (uV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Median nerve (APB) (R)		<u> </u>	<u> </u>
CMAP (mV)	NR	NR	4.8
CV (m/s)	NR	NR	41
Ulnar nerve (ADM) (R)			
CMAP (mV)	2	0.6	6.6
CV (m/s)	44.4	44.7	52 (wrist-below elbow)
			57 (wrist-above elbow)
Peroneal nerve (EDB) (R)			<u> </u>
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Tibial nerve (FHB) (L)			
CMAP (mV)	NR	NR	NR
CV (m/s)	NR	NR	NR
Needle EMG	Absent voluntary units in the right tibilias anterior and medial gastrocnemius muscles, as well as denervation-reinnervation changes in	Absent recruitment of motor units in the right tibialis anterior, medical gastrocnemius, first dorsal interosseous and vastus lateralis	Reduced recruitment of motor units in the right tibialis interior and right vastus medialis muscles. Discrete recruitment of muscle fibres in the

the right vastus lateralis muscle.	muscles. Denervation-reinnervation	right gastrocnemius muscle.
	changes were evident in the right	
	deltoid, biceps brachii and triceps	
	brachii muscles.	



